

Gui-Qi Zhu

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/42922/gui-qi-zhu-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

58

papers

898

citations

17

h-index

26

g-index

61

ext. papers

1,147

ext. citations

4.4

avg, IF

4

L-index

#	Paper	IF	Citations
58	Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.. <i>BMC Cancer</i> , 2022 , 22, 316	4.8	1
57	Risk stratification of LI-RADS M and LI-RADS 4/5 combined hepatocellular cholangiocarcinoma: prognostic values of MR imaging features and clinicopathological factors.. <i>European Radiology</i> , 2022 , 1	8	0
56	Crosstalk Between Metabolism and Immune Activity Reveals Four Subtypes With Therapeutic Implications in Clear Cell Renal Cell Carcinoma.. <i>Frontiers in Immunology</i> , 2022 , 13, 861328	8.4	1
55	Splicing factor SRSF1 promotes breast cancer progression via oncogenic splice switching of PTPMT1. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021 , 40, 171	12.8	6
54	Splicing factors: Insights into their regulatory network in alternative splicing in cancer. <i>Cancer Letters</i> , 2021 , 501, 83-104	9.9	7
53	Identification and validation of a new gene signature predicting prognosis of hepatocellular carcinoma patients by network analysis of stemness indices. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021 , 15, 699-709	4.2	3
52	A multidimensional nomogram combining imaging features and clinical factors to predict the invasiveness and metastasis of combined hepatocellular cholangiocarcinoma. <i>Annals of Translational Medicine</i> , 2021 , 9, 1518	3.2	2
51	Exosomal miR-3682-3p Suppresses Angiogenesis by Targeting ANGPT1 via the RAS-MEK1/2-ERK1/2 Pathway in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 633358	5.7	7
50	Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study. <i>Molecular Oncology</i> , 2021 ,	7.9	2
49	Profiles of alternative splicing landscape in breast cancer and their clinical significance: an integrative analysis based on large-sequencing data. <i>Annals of Translational Medicine</i> , 2021 , 9, 58	3.2	1
48	Identification and validation of tumour microenvironment-based immune molecular subgroups for gastric cancer: immunotherapeutic implications. <i>Cancer Immunology, Immunotherapy</i> , 2020 , 69, 1057-1069	7.4	20
47	MACROD2 deficiency promotes hepatocellular carcinoma growth and metastasis by activating GSK-3 β /catenin signaling. <i>Npj Genomic Medicine</i> , 2020 , 5, 15	6.2	7
46	Genetic Alterations and Transcriptional Expression of mA RNA Methylation Regulators Drive a Malignant Phenotype and Have Clinical Prognostic Impact in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2020 , 10, 900	5.3	3
45	HNRNPAB-regulated lncRNA-ELF209 inhibits the malignancy of hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2020 , 146, 169-180	7.5	17
44	Comparative efficacy and safety of immunosuppressive therapies for systemic sclerosis related interstitial lung disease: A Bayesian network analysis. <i>Modern Rheumatology</i> , 2020 , 30, 687-695	3.3	8
43	Survival-Associated Alternative Messenger RNA Splicing Signatures in Pancreatic Ductal Adenocarcinoma: A Study Based on RNA-Sequencing Data. <i>DNA and Cell Biology</i> , 2019 , 38, 1207-1222	3.6	3
42	Development and validation of a new tumor-based gene signature predicting prognosis of HBV/HCV-included resected hepatocellular carcinoma patients. <i>Journal of Translational Medicine</i> , 2019 , 17, 203	8.5	10

41	Prognostic alternative mRNA splicing signature in hepatocellular carcinoma: a study based on large-scale sequencing data. <i>Carcinogenesis</i> , 2019 , 40, 1077-1085	4.6	23
40	The miR-561-5p/CXCL1 Signaling Axis Regulates Pulmonary Metastasis in Hepatocellular Carcinoma Involving CXCR1 Natural Killer Cells Infiltration. <i>Theranostics</i> , 2019 , 9, 4779-4794	12.1	43
39	Comparative Effectiveness of Radiofrequency Ablation, Surgical Resection and Transplantation for Early Hepatocellular Carcinoma by Cancer Risk Groups: Results of Propensity Score-Weighted Analysis. <i>Oncotargets and Therapy</i> , 2019 , 12, 10389-10400	4.4	4
38	Long-Term Survival Differences Between T1-2 Invasive Lobular Breast Cancer and Corresponding Ductal Carcinoma After Breast-Conserving Surgery: A Propensity-Scored Matched Longitudinal Cohort Study. <i>Clinical Breast Cancer</i> , 2019 , 19, e101-e115	3	7
37	Aspartate aminotransferase-to-platelet ratio index predicts prognosis of hepatocellular carcinoma after postoperative adjuvant transarterial chemoembolization. <i>Cancer Management and Research</i> , 2019 , 11, 63-79	3.6	8
36	Efficacy of prophylactic probiotics in combination with antibiotics versus antibiotics alone for colorectal surgery: A meta-analysis of randomized controlled trials. <i>Journal of Surgical Oncology</i> , 2018 , 117, 1394-1404	2.8	11
35	Comparative efficacy and safety between ablative therapies or surgery for small hepatocellular carcinoma: a network meta-analysis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018 , 12, 935-945	4.2	10
34	Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis. <i>Expert Review of Anti-Infective Therapy</i> , 2017 , 15, 503-513	5.5	14
33	Serum uric acid: a new therapeutic target for nonalcoholic fatty liver disease. <i>Expert Opinion on Therapeutic Targets</i> , 2016 , 20, 375-87	6.4	16
32	Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma. <i>Scientific Reports</i> , 2016 , 6, 33743	4.9	38
31	The role of lncRNAs in hepatocellular carcinoma: opportunities as novel targets for pharmacological intervention. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016 , 10, 331-40	4.2	16
30	Kidney bioengineering in regenerative medicine: An emerging therapy for kidney disease. <i>Cytotherapy</i> , 2016 , 18, 186-97	4.8	14
29	Stratified neutrophil-to-lymphocyte ratio accurately predict mortality risk in hepatocellular carcinoma patients following curative liver resection. <i>Oncotarget</i> , 2016 , 7, 5429-39	3.3	15
28	Increased levels of low-density lipoprotein cholesterol within the normal range as a risk factor for nonalcoholic fatty liver disease. <i>Oncotarget</i> , 2016 , 7, 5728-37	3.3	25
27	Parabolic relationship between sex-specific serum high sensitive C reactive protein and non-alcoholic fatty liver disease in Chinese adults: a large population-based study. <i>Oncotarget</i> , 2016 , 7, 14241-50	3.3	5
26	Preoperative platelet to lymphocyte ratio is a valuable prognostic biomarker in patients with colorectal cancer. <i>Oncotarget</i> , 2016 , 7, 25516-27	3.3	43
25	Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma. <i>Oncotarget</i> , 2016 , 7, 21753-62	3.3	55
24	Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation. <i>Oncotarget</i> , 2016 , 7, 30642-58	3.3	40

23	Establishment and Validation of GV-SAPS II Scoring System for Non-Diabetic Critically Ill Patients. <i>PLoS ONE</i> , 2016 , 11, e0166085	3.7	8
22	Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1. <i>Medicine (United States)</i> , 2016 , 95, e3004	1.8	22
21	Platelet-to-Lymphocyte Ratio: A Novel Prognostic Factor for Prediction of 90-day Outcomes in Critically Ill Patients With Diabetic Ketoacidosis. <i>Medicine (United States)</i> , 2016 , 95, e2596	1.8	16
20	Comparative efficacy of oral nucleotide analogues for the prophylaxis of hepatitis B virus recurrence after liver transplantation: a network meta-analysis. <i>Expert Review of Anti-Infective Therapy</i> , 2016 , 14, 979-87	5.5	11
19	Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy. <i>Alimentary Pharmacology and Therapeutics</i> , 2015 , 41, 624-35	6.1	57
18	Decellularization technology in CNS tissue repair. <i>Expert Review of Neurotherapeutics</i> , 2015 , 15, 493-500	4.3	16
17	Network meta-analysis of randomized controlled trials: efficacy and safety of UDCA-based therapies in primary biliary cirrhosis. <i>Medicine (United States)</i> , 2015 , 94, e609	1.8	16
16	Nonalcoholic fatty liver disease: a negative risk factor for colorectal cancer prognosis. <i>Medicine (United States)</i> , 2015 , 94, e479	1.8	15
15	Systematic review with network meta-analysis: adjuvant chemotherapy for resected colorectal liver metastases. <i>Medicine (United States)</i> , 2015 , 94, e379	1.8	8
14	New advances in liver decellularization and recellularization: innovative and critical technologies. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015 , 9, 1183-91	4.2	6
13	Autophagy in ethanol-exposed liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015 , 9, 1031-7	4.2	8
12	Increased levels of systolic blood pressure within the normal range are associated with significantly elevated risks of nonalcoholic fatty liver disease. <i>Medicine (United States)</i> , 2015 , 94, e842	1.8	22
11	Optimal adjuvant therapy for resected hepatocellular carcinoma: a systematic review with network meta-analysis. <i>Oncotarget</i> , 2015 , 6, 18151-61	3.3	33
10	Establishment and Validation of SSCLIP Scoring System to Estimate Survival in Hepatocellular Carcinoma Patients Who Received Curative Liver Resection. <i>PLoS ONE</i> , 2015 , 10, e0129000	3.7	10
9	Recent advances in re-engineered liver: de-cellularization and re-cellularization techniques. <i>Cytotherapy</i> , 2015 , 17, 1015-24	4.8	3
8	Association between sex-specific serum uric acid and non-alcoholic fatty liver disease in Chinese adults: a large population-based study. <i>Medicine (United States)</i> , 2015 , 94, e802	1.8	40
7	Combined AFP-CRUT with microvascular invasion accurately predicts mortality risk in patients with hepatocellular carcinoma following curative liver resection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015 , 9, 1127-38	4.2	2
6	Targeting fibroblast growth factor 19 in liver disease: a potential biomarker and therapeutic target. <i>Expert Opinion on Therapeutic Targets</i> , 2015 , 19, 675-85	6.4	19

5	Metabolic syndrome contributes to an increased recurrence risk of non-metastatic colorectal cancer. <i>Oncotarget</i> , 2015 , 6, 19880-90	3.3	32
4	Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis. <i>Oncotarget</i> , 2015 , 6, 24533-49	3.3	10
3	Conditional survival estimate of acute-on-chronic hepatitis B liver failure: a dynamic prediction based on a multicenter cohort. <i>Oncotarget</i> , 2015 , 6, 23261-71	3.3	12
2	A network meta-analysis of the efficacy and side effects of UDCA-based therapies for primary sclerosing cholangitis. <i>Oncotarget</i> , 2015 , 6, 26757-69	3.3	20
1	Systematic review with network meta-analysis: adjuvant therapy for resected biliary tract cancer. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 40, 759-70	6.1	26